SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.


Already have an account? Log in here

GC012F Results in MM and NHL to Be Presented at ASCO and EHA; New GC012F Trial in SLE; GC007g Demonstrates Remarkable Ph1 IIT Results in ALL; Gracell’s Q1 2023 Earnings Call Summary

Here is a brief preview of this blast: On Monday, May 15, Gracell held its Q1 2023 earnings call (press release) highlighting the presentation of results from GC012F (BCMA x CD19 FasTCAR-T) and GC007g (allogeneic CD19 CAR-T) in several hematological indications at ASCO and EHA 2023, while disclosing the initiation of a Ph1 IIT evaluating GC012F in refractory systemic lupus erythematosus (SLE). Below, Celltelligence provides insights on the interest of Gracell in establishing a collaboration for the development of the GC012F's Ph1b/2 trial for ≥4L MM to be initiated in the US, while comparing GC012F to its main competitors in the SLE field.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.